Information Provided By: 
Fly News Breaks for April 26, 2019
ZFGN
Apr 26, 2019 | 08:22 EDT
Roth Capital analyst Yasmeen Rahimi initiated Zafgen with a Buy rating and $8 price target, stating that she has high conviction that the company can clear the hurdles of the clinical hold placed on ZGN-1061 and the suspension of the IND filing of ZGN-1258. She believes the FDA's issuance of the complete clinical hold may have been overly cautious, but "should be easily overcome," after which Rahimi believes ZGN-1061's weight loss profile is likely to attract large pharma interest.
News For ZFGN From the Last 2 Days
There are no results for your query ZFGN
